Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER ® and RE-COVER II™

Sebastian Schellong, MD, Henry Eriksson, MD PhD, Samuel Z. Goldhaber, MD, Martin Feuring, MD, Stefan Hantel, PhD, Jörg Kreuzer, MD, Sam Schulman, MD PhD, Ajay K Kakkar, MB, BS, PhD

Blood (2015) 126 (23): 4730.

https://doi.org/10.1182/blood.V126.23.4730.4730

Published: 2015

Journal Articles

Post-Hoc Analysis of RE-MEDY™ Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism

Sam Schulman, MD PhD, Henry Eriksson, MD PhD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Patrick Mismetti, MD PhD, Martin Feuring, MD, Stefan Hantel, PhD, Joerg Kreuzer, MD, Samuel Z. Goldhaber, MD

Blood (2014) 124 (21): 4270.

https://doi.org/10.1182/blood.V124.21.4270.4270

Published: 2014

Journal Articles

Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER™ and RE-COVER™ II

Sam Schulman, MD PhD, Henry Eriksson, MD PhD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Patrick Mismetti, MD, Martin Feuring, MD, Stefan Hantel, PhD, Joerg Kreuzer, MD, Samuel Z. Goldhaber, MD

Blood (2014) 124 (21): 594.

https://doi.org/10.1182/blood.V124.21.594.594

Published: 2014

Journal Articles

Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDY™

Sam Schulman, MD PhD, Henry Eriksson, MD PhD, Samuel Z. Goldhaber, MD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Martin Feuring, MD, Jeffrey Friedman, MD, Joerg Kreuzer, MD

Blood (2014) 124 (21): 1544.

https://doi.org/10.1182/blood.V124.21.1544.1544

Published: 2014

Journal Articles

Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Sam Schulman, MD, PhD, Henry Eriksson, MD, PhD, Samuel Z Goldhaber, MD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Martin Feuring, MD, Nuala Peter, BSc (Hons), Jeffrey Friedman, MD

Blood (2013) 122 (21): 1136.

https://doi.org/10.1182/blood.V122.21.1136.1136

Published: 2013

Journal Articles

Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Blood (2013) 122 (21): 582.

https://doi.org/10.1182/blood.V122.21.582.582

Published: 2013

Journal Articles

Influence Of Renal Function On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Blood (2013) 122 (21): 212.

https://doi.org/10.1182/blood.V122.21.212.212

Published: 2013

Journal Articles

Real-World Study of Dabigatran Etexilate for Thromboprophylaxis in Over 5000 Hip or Knee Replacement Patients: Favourable Safety Profile in Subgroups with Different BMI, Renal Function and Age

Nadia Rosencher, MD, Simon Frostick, MD, Martin Feuring, MD, Eva Kleine, Martina Brueckmann, MD, Andreas Clemens, MD, Charles Marc Samama, MD

Blood (2012) 120 (21): 1160.

https://doi.org/10.1182/blood.V120.21.1160.1160

Published: 2012

Journal Articles

Epidemiological Data On the Incidence of Co-Morbidities and Co-Medications in Patients Undergoing Total Hip or Knee Replacement Surgery: Real-World Study and Phase III Clinical Trials.

Nadia Rosencher, MD, Simon Frostick, MD, Martin Feuring, MD, Eva Kleine, Martina Brueckmann, MD, Andreas Clemens, MD, Charles Marc Samama, MD

Blood (2012) 120 (21): 2269.

https://doi.org/10.1182/blood.V120.21.2269.2269

Published: 2012

Journal Articles

Validation of the HEMOCLOT ® Direct Thrombin Inhibitor Assay for Dabigatran by Comparison with a Validated LC-MS/MS Method in Plasma Samples From Patients After Major Orthopaedic Surgery

Joachim Stangier, PhD, Bengt I Eriksson, MD, Michael H Huo, MD, Richard J Friedman, MD, Ola E Dahl, MD, Martin Feuring, MD

Blood (2011) 118 (21): 2307.

https://doi.org/10.1182/blood.V118.21.2307.2307

Published: 2011

Journal Articles

Evaluation of the Acute Coronary Syndrome Safety Profile of Dabigatran Etexilate in Patients Undergoing Major Orthopaedic Surgery: Findings From Four Phase III Trials

Bengt I Eriksson, MD, John J Smith, MD, PhD, Joseph Caprini, MD, Stefan Hantel, PhD, Andreas Clemens, MD, Martin Feuring, MD, Gregory W Barsness, MD

Blood (2011) 118 (21): 2309.

https://doi.org/10.1182/blood.V118.21.2309.2309

Published: 2011

Journal Articles

Oral Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty: A Pooled Analysis of Four Randomized Trials

Michael H Huo, MD, Andreas A Kurth, MD, Ola E Dahl, MD, Andreas Clemens, MD, Stefan Hantel, PhD, Martin Feuring, MD, Richard J Friedman, MD, Bengt I Eriksson, MD, PhD

Blood (2011) 118 (21): 2312.

https://doi.org/10.1182/blood.V118.21.2312.2312

Published: 2011

NARROW

Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER ® and RE-COVER II™

Post-Hoc Analysis of RE-MEDY™ Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism

Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER™ and RE-COVER™ II

Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDY™

Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Influence Of Renal Function On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Real-World Study of Dabigatran Etexilate for Thromboprophylaxis in Over 5000 Hip or Knee Replacement Patients: Favourable Safety Profile in Subgroups with Different BMI, Renal Function and Age

Epidemiological Data On the Incidence of Co-Morbidities and Co-Medications in Patients Undergoing Total Hip or Knee Replacement Surgery: Real-World Study and Phase III Clinical Trials.

Validation of the HEMOCLOT ® Direct Thrombin Inhibitor Assay for Dabigatran by Comparison with a Validated LC-MS/MS Method in Plasma Samples From Patients After Major Orthopaedic Surgery

Evaluation of the Acute Coronary Syndrome Safety Profile of Dabigatran Etexilate in Patients Undergoing Major Orthopaedic Surgery: Findings From Four Phase III Trials

Oral Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty: A Pooled Analysis of Four Randomized Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only